Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00301080 · ClinicalTrials.gov registry record · Phase 3
D-cycloserine in the Management of Chemotherapy-Induced Peripheral Neuropathic Pain
A Phase 3 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 7
- Enrollment target
NCT00301080: Clinical Trial Phase 3 study, sponsored by Northwestern University.
NCT00301080 is a Phase 3 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 7 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00301080, a Phase 3 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 7 participants
- Enrollment target
Study Summary
D-cycloserine may help lessen pain and other symptoms of peripheral neuropathy caused by chemotherapy. It is not yet known whether D-cycloserine is more effective than a placebo in treating peripheral neuropathy caused by chemotherapy. This randomized, double-blind, placebo-controlled clinical trial was designed to study D-cycloserine at 2 different doses to see how well each works compared to the other and to a placebo in treating cancer patients with peripheral neuropathy caused by chemotherapy.
Primary Outcome
Compare patient-reported pain intensity scores after the treatment period (12 weeks) between the 3 arms of the trial.
Interventions
- OTHER Placebo
- DRUG D-cycloserine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2006-02 |
| Est. Completion | 2008-05 |
| Phase | Phase 3 |
Why NCT00301080 stopped before completion
NCT00301080 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00301080 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00301080 about?
NCT00301080 is a clinical study titled "D-cycloserine in the Management of Chemotherapy-Induced Peripheral Neuropathic Pain". D-cycloserine may help lessen pain and other symptoms of peripheral neuropathy caused by chemotherapy. It is not yet known whether D-cycloserine is more effective than a placebo in treating peripheral neuropathy caused by chemotherapy. This randomized, double-blind, placebo-controlled clinical tria...
What is the current status of trial NCT00301080?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 7 participants. The study started on 2006-02. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00301080?
The interventions under investigation include: Placebo (OTHER), D-cycloserine (DRUG).
Who is sponsoring clinical trial NCT00301080?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00301080's enrollment target sits among peer trials
7 1995th of 2000 higher than 6 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia